News & Updates
Filter by Specialty:
Show Multimedia Only

Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma
15 hours ago
byStephen Padilla
Patients with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma demonstrate significant improvements in event-free survival (EFS) following treatment with durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy compared with placebo plus FLOT, as shown by the results of the phase III MATTERHORN study.
Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma
15 hours ago
CtDNA-guided surveillance catches postoperative CRC recurrences early for curative treatment
01 Sep 2025
byJairia Dela Cruz
For patients who have undergone curative resection for nonmetastatic colorectal cancer (CRC), performing circulating tumour DNA (ctDNA) methylation analysis during surveillance facilitates earlier detection of recurrences suitable for curative therapy, according to interim data from the phase III FIND trial.